Post-Conference Perspectives: Key Takeaways From Recent Psoriasis Abstracts
Aaron Farberg, MD, discusses how real-world studies like tildrakizumab’s help confirm efficacy and adherence outside trials, with multisite inclusion enhancing generalizability. Results aligned with clinical trials, highlighting better adherence. The VISIBLE study emphasized comorbidity impact, influencing clinical decisions and payer perspectives. Biosimilars’ role in clinical trials ensures safety and efficacy, with interchangeability gaining clinical adoption.
Episodes
March 28th 2025EP. 1: Real-World Insights on Tildrakizumab
An expert discusses how the study assessed real-world effectiveness of tildrakizumab for moderate to severe plaque psoriasis, crucial for validating clinical trial results. Multisite data enhanced reliability, while a systematic review and meta-analysis confirmed efficacy, safety, and quality of life benefits, aligning with trial findings.
April 8th 2025EP. 2: Tildrakizumab in Practice: Adherence and Clinical Takeaways
An expert discusses how health care provider administration may improve adherence to tildrakizumab. The meta-analysis confirms its real-world efficacy, safety, and quality of life benefits, supporting clinical use. These findings may influence payer decisions by reinforcing its value and long-term effectiveness in psoriasis care.
April 22nd 2025EP. 4: Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab
An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, persistence, adherence, and switching. Results showed favorable persistence and adherence. Provider administration may have influenced outcomes, impacting clinical decisions.
